**Supplementary Table 2. ‘Benefit-Satisfaction-Willingness to continue’ at the end of treatment (full analysis set)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Placebo**  **(N=71)** | **DA-8010 2.5mg**  **(N=68)** | **DA-8010 5mg**  **(N=68)** | **Solifenacin 5mg**  **(N=70)** |
| **Benefit** |  |  |  |  |
| **No** | 18(25.00) | 11(15.71) | 12(16.90) | 10(13.89) |
| No benefit | 18(25.00) | 11(15.71) | 12(16.90) | 10(13.89) |
| **Yes** | 53(73.61) | 57(81.43) | 56(78.87) | 60(83.33) |
| Little benefit | 24(33.33) | 28(40.00) | 27(38.03) | 23(31.94) |
| Much benefit | 29(40.28) | 29(41.43) | 29(40.85) | 37(51.39) |
| P-value [1] |  | 0.4245 | 0.4608 |  |
| **Satisfaction** |  |  |  |  |
| **No** | 25(34.72) | 19(27.14) | 16(22.54) | 16(22.22) |
| Very dissatisfied | 9(12.50) | 6(8.57) | 5(7.04) | 5(6.94) |
| A little dissatisfied | 16(22.22) | 13(18.57) | 11(15.49) | 11(15.28) |
| **Yes** | 46(63.89) | 49(70.00) | 52(73.24) | 54(75.00) |
| A little satisfied | 30(41.67) | 30(42.86) | 34(47.89) | 29(40.28) |
| Very satisfied | 16(22.22) | 19(27.14) | 18(25.35) | 25(34.72) |
| P-value [1] |  | 0.3188 | 0.1739 |  |
| **Willingness to Continue** |  |  |  |  |
| **No** | 41(56.94) | 28(40.00) | 19(26.76) | 21(29.17) |
| Very unwilling | 16(22.22) | 9(12.86) | 8(11.27) | 8(11.11) |
| A little bit unwilling | 25(34.72) | 19(27.14) | 11(15.49) | 13(18.06) |
| **Yes** | 30(41.67) | 40(57.14) | 49(69.01) | 49(68.06) |
| A little bit willing | 21(29.17) | 23(32.86) | 35(49.30) | 24(33.33) |
| Very willing | 9(12.50) | 17(24.29) | 14(19.72) | 25(34.72) |
| P-value [1] |  | 0.0238 | 0.0030 |  |

The number of each cell represents the number (%) of the patient

The denominator used to calculate the percentage is the total number of FAS patients in each group; 72 in Placebo, 70 in DA-8010 2.5mg, 71 in the DA-8010 5mg, and 72 in Solifenacin 5mg group

The results of the solifenacin 5mg group were added for exploratory analysis

[1] Cochran-Mantel-Haenszel test after controlling for gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo